ClinicalTrials.gg
Not yet recruitingNCT07628192Updated Oct 7, 2026

Youth Suicide Prevention: CAMS-BI vs. Safety Planning in a Randomized Trial

An interventional study of CAMS Brief Intervention and Stanley-Brown Safety Planning Intervention in Suicidal Ideation, Suicide Attempt and Safety Plan, sponsored by The Cleveland Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Health services research

How we know

Updated Oct 7, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 350 studies in Suicidal Ideation with a site in United States — 110 open to participants now, 123 under way, 4 of them phase 3. Suicidal Ideation · United States.

Planned enrollment
103rd of 321
118 · median 66
Started
2026
with 37 others
No phase
255 of 350
94 open now
Primary completion
2027-12
later than 79 of 122 live
Registered
332nd of 350
by date

Among the 350 studies in Suicidal Ideation with a site in United States, this one is the 103rd largest by planned enrollment of the 321 interventional ones that give a count, is one of 38 that started in 2026, is one of 255 with no phase, reaches primary completion later than 79 of the 122 other live ones, and was the 332nd registered.

Suicidal Ideation

570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.

Browse Suicidal Ideation studies →

Open to participants now

110 of the 350 studies in Suicidal Ideation with a site in United States are open now. Recruiting first, the newest first:

105 more — sign in →

All 110 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 350 studies in Suicidal Ideation with a site in United States, or all of them as a file.
02

Study summary

This study outlines a randomized controlled trial evaluating two brief suicide-specific interventions for adolescents aged 12-17 who are hospitalized for suicidal ideation or attempts. Suicide remains a leading cause of death among youth, and many adolescents are discharged from inpatient care without targeted, suicide-focused treatment, contributing to high rates of readmission and ongoing risk. This study seeks to address that gap by comparing the effectiveness of the Collaborative Assessment and Management of Suicidality-Brief Intervention (CAMS-BI) with the Stanley-Brown Safety Planning Intervention (SPI), both delivered as single-session interventions during inpatient hospitalization.

Participants (N=118) will be randomly assigned to receive either CAMS-BI or SPI. CAMS-BI is a therapeutic, collaborative framework that focuses on identifying and addressing the underlying psychological drivers of suicidality, while SPI is a structured, practical approach that emphasizes immediate safety through coping strategies, support systems, and means restriction. Following the intervention, participants will be monitored for 90 days post-discharge, with follow-ups at 30, 60, and 90 days.

The primary outcome is the rate of psychiatric readmissions and suicide-related emergency department visits within 90 days of discharge. Secondary outcomes include changes in suicidal ideation, measured by the Beck Scale for Suicide Ideation, and caregiver confidence in managing their child's safety. Additional measures include distress levels, hopelessness, treatment satisfaction, and engagement.

The study hypothesizes that CAMS-BI will result in lower readmission rates, greater reductions in suicidal ideation, and improved caregiver confidence compared to SPI. Both interventions produce individualized safety or stabilization plans that are shared with patients and caregivers and incorporated into discharge planning to support continuity of care.

Safety protocols are emphasized throughout the study, given the high-risk population. Participants receive standard clinical care, crisis resources, and close monitoring, with procedures in place to address any escalation in suicide risk. Data will be collected using secure systems, and confidentiality will be maintained through de-identification and controlled access.

Overall, this study aims to determine whether a rapid, inpatient, suicide-focused intervention can improve short-term outcomes for high-risk youth and reduce the likelihood of rehospitalization, ultimately informing scalable approaches to suicide prevention in clinical settings.

Read the detailed description

This single-site randomized controlled trial evaluates two brief suicide-specific interventions for adolescents hospitalized for suicidal ideation or suicide attempts at Cleveland Clinic Children's. The study compares the Collaborative Assessment and Management of Suicidality-Brief Intervention (CAMS-BI) with the Stanley-Brown Safety Planning Intervention (SPI) to determine their effectiveness in reducing suicide-related psychiatric readmissions and emergency department utilization following inpatient psychiatric hospitalization.

Adolescent suicide remains a major public health concern and is one of the leading causes of death among youth ages 10-24 years. Psychiatric hospitalization provides an important opportunity to intervene following suicidal crises; however, many adolescents are discharged without receiving a structured suicide-focused therapeutic intervention beyond standard stabilization and discharge planning. Brief, scalable interventions that can be delivered during hospitalization may improve continuity of care and reduce recurrent suicidal crises after discharge.

Participants are adolescents ages 12-17 years admitted for suicidal ideation or suicide attempts. Eligible participants are randomized in a 1:1 ratio to receive either CAMS-BI or SPI during their inpatient admission. Randomization is stratified by gender and implemented using REDCap block randomization procedures.

CAMS-BI is a collaborative, suicide-focused therapeutic intervention adapted from the Collaborative Assessment and Management of Suicidality framework. The intervention uses the Suicide Status Form (SSF) to identify and target the psychological drivers of suicidality, including hopelessness, psychological pain, agitation, and self-hate. Sessions emphasize collaborative assessment, treatment planning, and therapeutic alliance.

SPI is a structured suicide prevention intervention focused on developing an individualized safety plan to support crisis management after discharge. The intervention includes identification of warning signs, coping strategies, supportive contacts, professional resources, and means restriction planning.

Participants complete study assessments at baseline, following the intervention, and during follow-up at 30, 60, and 90 days after discharge. Clinical outcomes include psychiatric readmissions, suicide-related emergency department visits, suicidal ideation severity, distress, hopelessness, caregiver confidence in crisis management, and participant satisfaction with the intervention.

Intervention fidelity is monitored through clinician training, structured supervision, and review of recorded intervention sessions using standardized fidelity measures specific to each intervention.

All participants continue to receive standard inpatient psychiatric treatment and discharge planning throughout study participation. Safety monitoring procedures are in place for escalation of suicide risk, including access to crisis intervention resources and clinical evaluation as needed. Study data are maintained in secure HIPAA-compliant systems.

The study is designed to determine whether a brief suicide-focused therapeutic intervention targeting the underlying drivers of suicidality provides additional benefit compared with structured safety planning alone in reducing short-term suicide-related outcomes among high-risk adolescents.

03

Conditions studied

  • Suicidal Ideation
  • Suicide Attempt
  • Safety Plan
  • Depression / Major Depressive Disorder
  • Hopelessness

Keywords

  • Youth suicide
  • Suicide ideation
  • Suicide attempt
  • Suicidal behavior
  • Depression
  • CAMS therapy
  • Safety plan
  • Hopelessness
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged 12-17 years.
  • Admitted to inpatient psychiatry for suicide attempt or active suicidal ideation.
  • English-speaking patient and parent/guardian.
  • Ability to understand and the willingness to sign a written informed assent document with a parent/guardian willing and able to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time).
  • Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis.
  • In custody of Children's Services.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Active comparator
    CAMS-BI

    Participants randomized to receive CAMS-BI intervention

    Behavioral: CAMS Brief Intervention

  • Active comparator
    Stanley Brown

    Participants randomized to Stanley Brown Safety Plan

    Behavioral: Stanley-Brown Safety Planning Intervention

Interventions

  • BehavioralCAMS Brief Intervention

    CAMS-BI is a brief, structured, suicide-focused psychotherapy delivered during inpatient hospitalization that uses the Suicide Status Form to collaboratively identify and directly target the patient's specific psychological drivers of suicidality (e.g., hopelessness, psychological pain, agitation, and self-hate). It emphasizes a strong therapeutic alliance and shared formulation to reduce suicidal risk and support linkage to ongoing care after discharge.

  • BehavioralStanley-Brown Safety Planning Intervention

    The Stanley-Brown Safety Planning Intervention (SPI) is a brief, structured, collaborative session in which the adolescent and clinician create a personalized written safety plan to use during future suicidal crises. The plan outlines warning signs, internal coping strategies, social supports, professional resources, and steps for restricting access to lethal means to help reduce immediate risk.

06

What researchers measure

Primary outcomes

  1. Reduction of inpatient psychiatry readmissions for suicide risk following CAMS-Brief Intervention VS Stanley-Brown Planning Intervention

    To compare CAMS-Brief Intervention VS Stanley-Brown Planning Intervention in reducing psychiatric readmissions and suicide-related emergency department (ED) visits within 90 days after discharge.

    Time frame: 90 days following discharge

Secondary outcomes

  1. Intensity of the Beck Scale for Suicide Ideation

    To compare interventions' effects on suicidal ideation intensity using the Beck Scale for Suicide Ideation (min 0, max 38)(higher scoring = more severe).

    Time frame: 90 days after discharge

  2. Improving caregiver confidence pre and post intervention using a 'Caregiver Confidence' 2 question scale

    To assess changes in caregiver confidence pre- and post-intervention in supporting suicidal youth and maintaining home safety using a 2 question scale.

    Time frame: 90 days post discharge

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 282 non-industry interventional studies with no phase under Suicidal Ideation, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 12 months is below that.

Counting every sponsor, half of 291 studies reached it within 30 months; a quarter within 13 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Aug 2026 → Dec 2026, primary completion Jan 2027 → Dec 2027 and completion Mar 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
Jun 4, 2026
StartEst.
Dec 1, 2026was Aug 2026
Primary completionEst.
Dec 30, 2027was Jan 2027
CompletionEst.
Jan 1, 2028was Mar 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 1, 2026
Oct 7, 2026
Primary completion
Jan 1, 2027→Dec 30, 2027
Oct 7, 2026
Study completion
Mar 1, 2027→Jan 1, 2028
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Aug 1, 2026→Dec 1, 2026
    Primary completion Jan 1, 2027→Dec 30, 2027
    Study completion Mar 1, 2027→Jan 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07628192
Responsible party
Tatiana Falcone, MD (Vice Chair of Research Behavioral Health and Neurological Science, Child and Adolescent Psychiatrist, Assistant Professor of Medicine, Principal Investigator, The Cleveland Clinic) — Principal investigator
First posted
Jun 4, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Christina A Deisz, LISW-S
Contact
deiszc@ccf.org
(440) 225-6193
Tatiana Falcone, M.D.
Contact
falcont1@ccf.org
(216) 444-7459
Tatiana Falcone, M.D.
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion